Continuing care after you fly home

Before discharge, obtain a complete summary naming the provider, clinician, product or procedure, cell source where applicable, dose, route, date and traceability details. Ask for immediate restrictions and warning signs in writing. Generic stem-cell recovery instructions cannot safely cover every route, condition or patient. Identify a local clinician willing to receive the record and manage ordinary care. They may not take responsibility for an unknown product without adequate documentation. Agree who answers routine questions and who assesses urgent symptoms. New severe or rapidly worsening symptoms require appropriate local or emergency care. Reconcile medicines with both the treating and usual clinician. Do not stop prescribed treatment or add supplements because of a claim that they affect cell integration. Follow wound, access-site or injection-site instructions specific to the procedure. Ask when bathing, exercise, driving, work and travel can resume. Use rehabilitation only after an individual assessment. Its goals and progression should reflect function and standard care, not a promised biological mechanism. Schedule protocol or clinical follow-up with named responsibilities. State which visits may be remote and what findings require examination, imaging or laboratory tests. Measure outcomes defined before treatment. Keep concurrent medicines, therapy and major health changes in the same record so results are not falsely attributed. Ask how adverse events are reported to the sponsor, manufacturer and competent authority. Keep the relevant trial or product identifiers available. Do not interpret a normal early check as proof of long-term safety. Some authorised products or trials require extended surveillance. Plan for communication failure, provider closure or staff turnover. Obtain a durable records contact and a route to the responsible authority. If the treatment occurred in a trial, confirm withdrawal rights and whether safety follow-up continues after stopping study procedures. If the intervention was commercial, clarify whether follow-up is included, time-limited or billed separately. Payment status should not block access to essential records. Keep consent, invoices, laboratory reports, images, discharge records and correspondence together. Record the date and source of every later correction. Tell any new clinician about the intervention before surgery, immunosuppression, imaging or other relevant care. Provide exact details rather than the generic term stem cells. Seek independent review when the provider attributes every symptom to healing, dismisses deterioration or repeatedly sells another cycle without objective reassessment. Protect mental health as part of recovery. Uncertainty, financial pressure and disappointment can require ordinary professional support. Do not travel back for repeat treatment until the first outcome, harms, alternatives and legal route have been reviewed again. Continuity of care is successful when local and treating teams have records, responsibilities and an escalation plan—not when a coordinator sends periodic messages.

Sources & further reading

• Stem-cell trials registry (ClinicalTrials.gov) ↗
• Peer-reviewed research (PubMed) ↗
• ISSCR — patient resources ↗
• FDA — consumer guidance ↗
• EMA — ATMP framework ↗

Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.